Quality Systems

The author discusses how to manage pending pharmacopeial changes.

No matter the upside or downside to the Affordable Care Act, there's work to be done.

Applying the recommendations of ICH Q10 to statistical analysis can help prevent product recalls.

IQ Consortium representatives explore industry approaches and practices for applying GMPs in early development.

New law provides FDA with the resources it needs to safeguard drug supply chain.

Meticulous system configuration can prevent machines from taking over.

The authors, part of the International Consortium on Innovation and Quality in Pharmaceutical Development (IQ Consortium), explore and define common industry approaches and practices when applying GMPs in early development.

The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.

FDA announces FY 2013 user fee rates and EMA furthers relationship with Japan.

A report from the European Commission shows that fake pharmaceuticals were the top articles detained by European Union customs in 2011.

A roundup of industry regulatory news.

Experts share insights into analytical tools and techniques.

FDA promotes supply chain pilot program. EMA opens pharmacovigilance legistation up for public consultation. USP Calls for Somatropin Cell-Based Bioidentity Method.

On July 9, 2012, Congress passed the Generic Drug User Fee Act in an effort to expedite the process of bringing generic drugs to market. The Act authorizes the collection of user fees from generic-drug manufacturing companies for the first time in the industry's history.

ISPE has issued a guidance that is intended to help companies meet cGMP requirements for packaging, labeling, and warehousing facilities and avoid problems such as product adulteration, product mix-up, label mix-up, and misbranding.

FDA has issued a draft guidance on the labeling of OTC products that contain acetaminophen. The draft guidance would give manufacturers an alternative option to properly clarify the risk of liver damage in OTC acetaminophen-containing products.

How FDA, USP, and ICH have redirected industry practice.

Experts share how to choose analytical tools and techniques when scaling up a lyophilization process.

EMA and MHRA provide insight into increased GMP deficiencies.

IQ Consortium representatives explore industry approaches for applying GMPs in early development.

Q&A with David Elder of Strategic Compliance Consulting, PAREXEL International on preparing for the rise in inspections. Elder is a former senior official with FDA.

Careful attention to detail will help to prevent valuable assets from "melting" away.

Taking time to appreciate the industry's greatest achievements will inspire growth ahead.

Readers point to quality by design as having a significant influence on manufacturing and drug development during the past decade.

A Q&A with FDA Deputy Commissioner Deborah Autor.